Appln. No. 10/613,836 Amdt. dated March 10, 2005 Reply to Office action of February 15, 2005

REMARKS

Claims 1-12 presently appear in this case. No claims have yet been acted upon on the merits. The official action of February 15, 2005, has now been carefully studied. Prompt consideration on the merits and allowance are hereby respectfully urged.

The examiner has required restriction to one of the following inventions:

Group I, including claims 1-12, drawn to a method for inhibiting aggregation of β -amyloid in a subject by administering a filamentous bacteriophage which displays an epitope of β -amyloid, and

Group II, including claims 13-17, drawn to a method for inhibiting aggregation of a prion protein in a subject by administering a filamentous bacteriophage which displays an epitope of a prion protein.

The examiner states that the inventions are distinct, each from the other.

Applicant hereby elects the claims of Group I.

Claims 13-17 have now been deleted without prejudice toward
the continuation of prosecution thereof in a divisional
application.

Appln. No. 10/618,856 Amdt. dated March 10, 2005 Reply to Office action of February 15, 2005

As all the claims now present in the case are directed toward the elected embodiment, prompt consideration on the merits and allowance are earnestly solicited.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C. Attorneys for Applicant(s)

Ву

Roger L. Browdy / Registration No. 25,618

RLB: jab

Telephone No.: (202) 628-5197 Facsimile No.: (202) 737-3528 G:\EN\R\ramg\\$olomon2A.1\FTO\AmdARespROA.doc

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office, on the date shown below.

Roger L. Browdy

Name

Signature

March 8, 2005

Date